The current study provides evidence that LMWF may serve as a potential therapeutic agent for acute renal IRI, and MAPK pathways especially JNK/p38-MAPK may be an appealing therapeutic target for AKI. The gene discussed is MAPK1; the disease is acute kidney injury.